Results 111 to 120 of about 261 (136)

Upfront blood microRNA test in LDCT-reluctant individuals: insights from the biomild trial. [PDF]

open access: yesJ Exp Clin Cancer Res
Sozzi G   +9 more
europepmc   +1 more source

Cell-free DNA and Fragmentomics as Biomarkers of Rheumatoid Arthritis Disease

open access: yesTurkish Journal of Osteoporosis
Hale Gök Dağıdır, Ayşegül Akbay
openaire   +1 more source

From multi-omics to deep learning: advances in cfDNA-based liquid biopsy for multi-cancer screening. [PDF]

open access: yesBiomark Res
Luo X   +13 more
europepmc   +1 more source

The role of circulating tumor DNA in gynecological cancer management. [PDF]

open access: yesFront Oncol
Gao M   +5 more
europepmc   +1 more source

A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles

open access: yesMolecular and Cellular Probes, 2022
Early detection is critical for minimizing mortality from cancer. Plasma cell-free DNA (cfDNA) contains the signatures of tumor DNA, allowing us to quantify the signature and diagnose early-stage tumors.
Kim, Jae Hyun   +25 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Science, 2021
Enhancing liquid biopsies Liquid biopsies, analyses of cell-free DNA that circulates in the blood, can be used in prenatal testing, oncology, and to monitor organ transplant recipients. Lo et al. review the nongenetic information that can be gleaned from analyses of cell-free DNA, which offers additional ...
Y. M. Dennis Lo   +3 more
openaire   +2 more sources

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology, 2023
The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment.
K T, Helzer   +33 more
openaire   +2 more sources

Quantitative Fragmentome Mapping Reveals Novel, Domain-specific Partners for the Modular Protein RepoMan (Recruits PP1 Onto Mitotic Chromatin at Anaphase) [PDF]

open access: yesMolecular and Cellular Proteomics, 2013
RepoMan is a protein phosphatase 1 (PP1) regulatory subunit that targets the phosphatase to key substrates throughout the cell cycle. Most work to date has focused on the mitotic roles of RepoMan/PP1, although equally important interphase role(s) have ...
Delphine Chamousset   +2 more
exaly   +2 more sources

Fragmentomics of proteins and natural oligopeptides

Biophysics, 2008
The term fragmentomics is grounded and defined. Theoretical structure-function analysis of all possible fragments of a protein molecule was performed under the concept of fragmentomics to determine the regions that could be potential sources of regulatory oligopeptides.
openaire   +3 more sources

Home - About - Disclaimer - Privacy